面动脉颊瓣修复口腔颌面部缺损的临床观察

目的探讨面动脉颊瓣修复口腔颌面部缺损的临床可靠性和修复效果。方法回顾分析淮安市第二人民医院口腔科2012年7月至2019年9月面动脉颊瓣修复口腔癌病灶切除术后缺损的患者15例,收集患者基本信息、病理诊断结果、手术时间、手术出血量及住院时间等资料,仔细临床检查,观察术区创口愈合情况,术后随访完善张口度功能检查,随访至少1年。数据采用SPSS 19.0统计软件分析处理,结果以x±s表示。结果观察随访面动脉颊瓣修复口腔颌面部缺损15例,平均手术时间(5.49±0.76)h,手术出血量约平均(382.67±63.86)mL,术中或术后输血3例,平均住院时间(17.73±2.49)d。面动脉颊瓣最大为8 cm×4 cm的三角形肌皮瓣。术后2周皮瓣均存活无坏死、血运良好,皮瓣存活率100%。术后1年复诊,医师检查患者张口度情况,15例患者张口度(3.86±0.14)cm,均在正常范围内。但3例男性患者提出术后皮瓣表面生长毛发,带来不适感,均在可以接受范围。位于口角以下颊部的供区瘢痕与面部纹路位置重叠。结论面动脉颊瓣可修复口腔中下部的中小缺损,皮瓣供区手术创伤小,皮瓣成活率高,可在口腔癌病灶切除后同期修复,术后张口功能恢复良好,瘢痕不明显。     

中药防治肺动脉高压研究现状及创新药物研发＊

肺动脉高压为恶性肺血管疾病或临床综合征，发病机理涉及复杂的生物学过程和多种分子机制，临床仍缺乏有效治疗药物。尽管单靶点药物的联合应用可有效改善其临床症状，但不能阻止病程进展，且价格昂贵，药物不良反应问题一直未能解决。中药因多成分协同作用、多靶点发挥药效、多途径整合调节疾病的特点，在肺动脉高压的治疗中发挥独特优势，具有良好应用前景和创新药物开发潜力。本文旨在全面系统地梳理近30年中药防治肺动脉高压的研究进展，分析创新药物研发的瓶颈及策略，以期为肺动脉高压的创新药物研发提供有益参考。     

Physical activity as a proxy to ameliorate inflammation in patients with type 2 diabetes and periodontal disease at high cardiovascular risk

While the beneficial impact of physical activity has been ascertained in a variety of pathological scenarios, including diabetes and low-grade systemic inflammation, its potential remains still putative for periodontal health. Periodontal disease has been associated with inflammatory systemic alterations, which share a common denominator with type 2 diabetes mellitus and cardiovascular disease. Physical exercise, along with nutritional counseling, is a cornerstone in the treatment and prevention of type 2 diabetes, also able to reduce the prevalence of periodontal disease and cardiovascular risk. In addition, considering the higher incidence of periodontitis in patients with type 2 diabetes compared to healthy controls, the fascinating research question would be whether physical activity could relieve the inflammatory pressure exerted by the combination of these two diseases. This multi-disciplinary viewpoint discusses available literature in order to argument the hypothesis of a “three–way relationship” linking diabetes, periodontitis, and physical activity.     

Cytochrome P450 2C19 enzyme,Cytochrome P450 2C9 enzyme,and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study

The objective of the present study was to assess the allelic variations of Cytochrome P450 (CYP) enzymes Cytochrome P450 2C19 (CYP2C19), Cytochrome P450 2C9 (CYP2C9), and Cytochrome P450 2D6 (CYP2D6) as they play a major role in drug metabolism. The interindividual genetic variabilities of these enzymes can account for different responsiveness as well as concentration fluctuations for a particular drug.During the period of 2017 to 2018 a total of 54 patients have received pharmacogenetic testing at the Department of Genetics and Molecular Medicine at Kaunas Clinics. According to the genotype-metabolic phenotypes of CYP2C19, CYP2D6, CYP2C9 enzymes patients were classified according to the guidelines by Clinical Pharmacogenetics Implementation Consortium (CPIC): normal metabolizers (NMs), intermediate metabolizers (IMs), rapid metabolizers (RMs), ultrarapid metabolizers (UMs), and poor metabolizers (PMs).CYP2C19 enzyme allelic distribution: 18 patients (33.33%) with ∗1/∗1 genotype were NMs; 14 patients (25.93%) with ∗1/∗2; ∗2/∗17 genotypes were classified as IMs; 15 patients (27.78%) possessed ∗1/∗17 genotype and were RMs; 4 patients (7.4%) had ∗17/∗17 genotype with increased enzyme activity compared with RMs, were classified as UMs; 3 patients (5.56%) had ∗2/∗2 genotype and were marked as PMs. CYP2D6 enzyme allelic distribution: 26 patients (48.148%) contained ∗1/∗1,∗2/∗2,∗1/∗2,∗1/∗41,∗2/∗41 genotypes with normal enzymatic function so were accounted as NMs; 21 patients (38.89%) with ∗1/∗5, ∗2/∗4, ∗10/∗41, ∗1/∗4, ∗1/∗3, ∗2/∗5, ∗2/∗4, ∗2/∗6 genotypes were accounted as IMs; 2 patients (3.7%) possessed ∗2XN genotype and were accounted as UMs and 5 patients (9.26%) possessed ∗4/∗5,∗4/∗10,∗4/∗9,∗4/∗41 genotypes and had non-functional enzymatic activity so were accounted as PMs; CYP2C9 enzyme allelic distribution: 44 patients (81.48%) with∗1/∗1 genotype were NMs; 10 patients (18.52%) with ∗1/∗2;∗1/∗3 genotypes were IMs.The results of our study indicate that deviations from the normal enzymatic activity is common amongst Lithuanian people and combinatory genotyping of CYP2D6, CYP2C9, and CYP2C19 has to be promoted as an advanced method because of most commonly prescribed medicines like analgesics, antihypertensive, antidepressants are metabolized by multiple pathways involving enzymes in the CYP450 family.     

Delayed pseudoaneurysm formation of the carotid artery following the oral cavity injury in a child: A case report

BACKGROUNDAn impalement injury of the oral cavity is a common traumatic injury in children. In most cases, it is not accompanied by sequelae, but if foreign body residues are not found due to a minor injury, they may result in inflammatory responses and delayed vascular injuries in the surrounding tissues. Without early diagnosis and appropriate initial management, residual foreign bodies can cause serious complications and even mortality in some cases. CASE SUMMARYA 9-year-old boy suffered an intra-oral injury by a wooden chopstick, and the patient was discharged from the hospital after receiving conservative treatment for the injury. However, the patient was readmitted to the hospital due to intra-oral bleeding, and since neck hematoma and right internal carotid artery pseudoaneurysm formation were detected on computed tomography, emergency surgery was performed. A remnant fragment of a wooden chopstick was found during the operation, and a delayed rupture of the internal carotid artery caused by the foreign body was also found.CONCLUSIONThe failure of early detection and diagnosis of a residual foreign body may result in delayed vascular rupture.     

Thymosin as a possible therapeutic drug for COVID-19: A case report

BACKGROUNDThere are no effective antiviral therapies for coronavirus disease 2019 (COVID-19) at present. Although most patients with COVID-19 have a mild or moderate course of disease, up to 5%-10% of patients may have a serious and potentially life-threatening condition, indicating an urgent need for effective therapeutic drugs. The therapeutic effect of thymosin on COVID-19 has not been previously studied. In this paper, for the first time we report a case of thymosin treatment of COVID-19.CASE SUMMARYA 51-year-old man with imported COVID-19 was admitted with definite symptoms of chest tightness, chest pain, and fatigue. The polymerase chain reaction results for severe acute respiratory syndrome coronavirus 2 were negative. The antibody test was positive, confirming the diagnosis of COVID-19. As many orally administered drugs were not well tolerated due to gastrointestinal symptoms, an emergency use of thymosin, a polypeptide consisting of 28 amino acids, was administered by injection. Finally, after the implementation of the treatment program, symptoms and lung imaging improved significantly.CONCLUSIONIn this case report, it is confirmed that thymosin may help alleviate the severity of COVID-19 symptoms.     

广东省慢性化脓性中耳炎患者耳分泌物的病原体分布及药物敏感性分析

目的分析广东省慢性化脓性中耳炎(CSOM)患者耳分泌物的病原体分布及药物敏感性情况,为临床CSOM的诊断和治疗提供依据。方法回顾性分析2015—2019年1892例确诊为CSOM患者耳分泌物标本的微生物学培养结果,对病原体分布、临床常用抗感染药物的敏感性进行分析。结果共检出1054株条件致病菌,检出率位于前3位的细菌是金黄色葡萄球菌、凝固酶阴性葡萄球菌和铜绿假单胞菌,真菌是近平滑念珠菌、聚多曲霉和黄曲霉。葡萄球菌对红霉素、青霉素G的敏感率较低,对其他常用抗菌药物的敏感率均高于70.0%,铜绿假单胞菌对于常用抗假单胞菌药物的敏感率均高于85.0%。近平滑念珠菌和白色念珠菌对氟康唑、伏立康唑均具有较高的敏感率;黄曲霉、土曲霉对两性霉素B的最小抑菌浓度(MIC)值较高,橘青霉对于伏立康唑的MIC值较高。结论广东省CSOM患者耳分泌物中病原体以葡萄球菌、铜绿假单胞菌、念珠菌和曲霉菌为主;真菌的检出率较其他地区高;检出的病原体对常用的治疗药物具有较高的敏感性。